One of them Benelong came here re: manufacturing and said SI said we're all good - "so that's good enough for me".
A month later JCR runs into manufacturing issues in Japan, and no announcement on their only approved product and revenue.
Bell Potter exposed it in broker report. The silence was deafening.
Then, the "reason offered up by these guys was "it's a demand issue"!!!
I have no idea how they will support Covid/ARDs or any large indication if they are now held up for 6 months treating just 200 patients pa.
Hence exactly why Cymerus exists as a business model.
Ann: Ethics Approval & Expedited Pathway for Phase 3 OA Trial, page-174
-
- There are more pages in this discussion • 322 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
-0.005(2.50%) |
Mkt cap ! $35.20M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.0¢ | 19.5¢ | $18.97K | 94.53K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4999 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| CYP (ASX) Chart |